|
Harbin Pharmaceutical Group Sanjing Pharmaceutical Co., Ltd. is a large pharmaceutical companies, scientific research , manufacturing, sales , trade in one country , and covers an area of two million square meters , with total assets of nearly 30 billion , with more than 3,000 employees produce operating 20 in of Western medicines size capacity injections , oral solutions , tablets , bulk drugs , formulations 334 454 varieties of product specifications . Three fine pharmaceutical , 2004 , the Shanghai Securities successfully listed on the 2008 operating income of 2.59 billion yuan , the total profit of 350 million yuan . Three fine pharmaceutical environment , resources have to expand the international competitiveness of products , and therefore in this context , the author, based on the actual situation of many years of work in the enterprise , and the use of the theoretical knowledge learned by the MBA , international competitiveness through product strategy theory research and analysis of three fine pharmaceutical products in the international competitive environment analysis and resource cost leadership strategy , the strategy of decentralization strategy and international competitiveness of the different product differentiation strategy . Established international competitive strategy countermeasures seek a strategic alliance to focus on the study of knowledge , shaping the cultural superiority , cost advantages , enhance the innovative mechanisms . The products international competition safeguards implementation of the strategy to strengthen the brand, enhance quality assurance , reasonable reserve personnel , strengthen institution building and strengthening research cooperation .
|